Literature DB >> 19908933

Impaired insulin secretion and uptake in patients with diffuse idiopathic skeletal hyperostosis.

M Eckertova1, K Krskova, A Penesova, Z Radikova, D Zlnay, J Rovensky, S Zorad.   

Abstract

OBJECTIVE: So far, high prevalence of metabolic symptoms accompanying diffuse idiopathic skeletal hyperostosis (DISH) appears not definitely elucidated because of their possible origin from other disorders such as diabetes and/or body mass differences. From such reasons this study was aimed to compare non-diabetic DISH patients to a group of age and BMI matched controls in order to distinguish the influence of DISH proper on metabolic parameters free of additional metabolic effects caused by diabetes and/or body weight differences.
METHODS: Both groups of patients were subjected to oral glucose tolerance test (OGTT) and fasting serum levels of glucose, insulin, C-peptide, growth hormone, insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGF-BP3) were assayed. Fasting serum total cholesterol, HDL cholesterol, triglycerides, non-esterified fatty acids (NEFA) and uric acid were determined as well. The indices of insulin sensitivity and insulin secretion were calculated.
RESULTS: With the exception of decreased NEFA serum level and decreased insulinogenic index and insulin/C-peptide ratio in DISH patients any other significant differences in serum parameters and indices of insulin sensitivity were not found.
CONCLUSIONS: The data obtained suggest impaired beta-cell pancreatic stimulation and increased insulin hepatic extraction in DISH. It is assumed that the above mentioned conditions, if persisting for a long time, might lead to decreased ability of insulin to maintain normal serum glucose level and consequently to insulin resistance which is highly prevalent in symptomatic DISH patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19908933

Source DB:  PubMed          Journal:  Endocr Regul        ISSN: 1210-0668


  8 in total

Review 1.  Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer.

Authors:  Robert G Maki
Journal:  J Clin Oncol       Date:  2010-10-25       Impact factor: 44.544

Review 2.  Diffuse idiopathic skeletal hyperostosis: clinical features and pathogenic mechanisms.

Authors:  Reuven Mader; Jorrit-Jan Verlaan; Dan Buskila
Journal:  Nat Rev Rheumatol       Date:  2013-11-05       Impact factor: 20.543

3.  Serum adiponectin levels in patients with diffuse idiopathic skeletal hyperostosis (DISH).

Authors:  Reuven Mader; I Novofastovski; N Schwartz; E Rosner
Journal:  Clin Rheumatol       Date:  2018-08-18       Impact factor: 2.980

Review 4.  Extraskeletal symptoms and comorbidities of diffuse idiopathic skeletal hyperostosis.

Authors:  Rabia Terzi
Journal:  World J Clin Cases       Date:  2014-09-16       Impact factor: 1.337

5.  The Prevalence and Characteristics of Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Cross-Sectional Study of 1519 Japanese Individuals.

Authors:  Hisanori Ikuma; Tomohiko Hirose; Dai Nakamura; Kazutaka Yamashita; Masataka Ueda; Kazuhiro Sasaki; Keisuke Kawasaki
Journal:  Diagnostics (Basel)       Date:  2022-04-27

6.  Metabolic factors in diffuse idiopathic skeletal hyperostosis - a review of clinical data.

Authors:  Sruti Pillai; Geoffrey Littlejohn
Journal:  Open Rheumatol J       Date:  2014-12-19

Review 7.  Diffuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next.

Authors:  Reuven Mader; Jorrit-Jan Verlaan; Iris Eshed; Jacome Bruges-Armas; Piercarlo Sarzi Puttini; Fabiola Atzeni; Dan Buskila; Eyal Reinshtein; Irina Novofastovski; Abdallah Fawaz; de Vlam Kurt; Xenofon Baraliakos
Journal:  RMD Open       Date:  2017-06-21

8.  Prevalence of diffuse idiopathic skeletal hyperostosis (DISH) assessed with whole-spine computed tomography in 1479 subjects.

Authors:  Akihiko Hiyama; Hiroyuki Katoh; Daisuke Sakai; Masato Sato; Masahiro Tanaka; Masahiko Watanabe
Journal:  BMC Musculoskelet Disord       Date:  2018-05-30       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.